Kimberly Maersk-Moller net worth and biography

Kimberly Maersk-Moller Biography and Net Worth

Chief Commercial Officer of MiMedx Group

Ms. Moller joined MIMEDX in August 2020 as Senior Vice President, Sales and was appointed Chief Commercial Officer in June 2024. She brings significant sales leadership experience, clinical knowledge and understanding of the Advanced Wound Care marketplace to her role. With more than 25 years of experience in sales roles with increasing responsibility, Ms. Moller has managed national sales teams and executed on strategic growth initiatives for leading healthcare companies, including 3M and its subsidiaries Acelity and KCI.

Ms. Moller holds a B.S. in Nursing (BSN) from University of Phoenix and an MBA from Colorado Christian University.

What is Kimberly Maersk-Moller's net worth?: The estimated net worth of Kimberly Maersk-Moller is at least $1.62 million as of November 6th, 2025. Ms. Maersk-Moller owns 236,982 shares of MiMedx Group stock worth more than $1,619,772 as of December 4th. This net worth evaluation does not reflect any other investments that Ms. Maersk-Moller may own. Learn More about Kimberly Maersk-Moller's net worth.
How do I contact Kimberly Maersk-Moller?: The corporate mailing address for Ms. Maersk-Moller and other MiMedx Group executives is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. MiMedx Group can also be reached via phone at (770) 651-9100 and via email at [email protected]. Learn More on Kimberly Maersk-Moller's contact information.
Has Kimberly Maersk-Moller been buying or selling shares of MiMedx Group?: During the past quarter, Kimberly Maersk-Moller has sold $432,586.00 in shares of MiMedx Group stock. Most recently, Kimberly Maersk-Moller sold 58,300 shares of the business's stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $7.42, for a transaction totalling $432,586.00. Following the completion of the sale, the insider now directly owns 236,982 shares of the company's stock, valued at $1,758,406.44. Learn More on Kimberly Maersk-Moller's trading history.
Who are MiMedx Group's active insiders?: MiMedx Group's insider roster includes Joseph Capper (CEO), William Hulse, IV (General Counsel and Chief Administrative and Compliance Officer), Kimberly Maersk-Moller (Chief Commercial Officer), Doug Rice (CFO), and Ricci Whitlow (COO). Learn More on MiMedx Group's active insiders.
Are insiders buying or selling shares of MiMedx Group?: In the last twelve months, MiMedx Group insiders bought shares 1 times. They purchased a total of 200,000 shares worth more than $1,268,000.00. In the last twelve months, insiders at the sold shares 6 times. They sold a total of 202,318 shares worth more than $1,562,898.34. The most recent insider tranaction occured on November, 6th when insider Kimberly Maersk-Moller sold 58,300 shares worth more than $432,586.00. Insiders at MiMedx Group own 1.7% of the company. Learn More about insider trades at MiMedx Group.
Information on this page was last updated on 11/6/2025.

Kimberly Maersk-Moller Insider Trading History at MiMedx Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/6/2025	Sell	58,300	$7.42	$432,586.00	236,982
3/17/2025	Sell	1,759	$8.04	$14,142.36	309,077
3/13/2025	Sell	4,106	$7.89	$32,396.34	310,836
2/28/2025	Sell	2,111	$8.40	$17,732.40	265,271

Kimberly Maersk-Moller Buying and Selling Activity at MiMedx Group

MiMedx Group Company Overview

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Today's Range

Now: $6.86

$6.78

$6.95

50 Day Range

MA: $7.00

$6.48

$7.96

2 Week Range

Now: $6.86

$5.79

$10.14

Volume

669,315 shs

Average Volume

768,000 shs

Market Capitalization

$1.02 billion

P/E Ratio

25.41

Dividend Yield

N/A

Beta

1.64